Skip to main content
Clinical Trials/NCT02459496
NCT02459496
Unknown
Not Applicable

Dietary Strategies to Improve Metabolism and Body Weight in Type 2 Diabetes

German Institute of Human Nutrition2 sites in 1 country200 target enrollmentSeptember 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 Diabetes
Sponsor
German Institute of Human Nutrition
Enrollment
200
Locations
2
Primary Endpoint
change in insulin secretion (glucagon stimulation test)
Last Updated
5 years ago

Overview

Brief Summary

Basic treatment of type 2 diabetes should focus on diet, physical activity and lifestyle. Nevertheless, in early and late stage of T2DM, lifestyle intervention is mostly substituted by pharmacological intervention, although lifestyle modification and dietary treatment would be favourable.

The researchers therefore investigate dietary strategies such as low-carb and very-low calory diets regarding their potential to improve metabolism and body weight in (mostly) long-term T2DM patients.

Detailed Description

Basic treatment of type 2 diabetes should focus on diet, physical activity and lifestyle. Nevertheless, in early and late stage of T2DM, lifestyle intervention is mostly substituted by pharmacological intervention, although lifestyle modification and dietary treatment would be favourable. The researchers therefore investigate dietary strategies such as low-carb diets and very-low calory diets regarding their potential to improve metabolism and body weight in (mostly) long-term T2DM patients. An intensive intervention of 3 weeks is followed by an 11-month maintenance phase to consolidate metabolic improvements.

Registry
clinicaltrials.gov
Start Date
September 2013
End Date
December 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. med. Andreas F. H. Pfeiffer

Director of the Department for Clinical Nutrition

German Institute of Human Nutrition

Eligibility Criteria

Inclusion Criteria

  • male and female subjects
  • 18-79 years old
  • type 2 diabetes

Exclusion Criteria

  • renal insufficiency
  • immunosuppression
  • previous symptomatic cancer diagnosis
  • acute cardiovascular disease (stroke, coronary syndrome)
  • pregnancy and lactation
  • severe psychiatric disorders
  • corticoid or other immunosuppressive therapy

Outcomes

Primary Outcomes

change in insulin secretion (glucagon stimulation test)

Time Frame: 3 weeks, 1 year

change in insulin secretion (glucagon stimulation test)

change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter

Time Frame: 3 weeks, 1 year

change in blood glucose profile in the mixed-meal tolerance test (MMTT) - combined parameter

change in hepatic fat content (MR-S)

Time Frame: 3 weeks, 1 year

change in hepatic fat content (MR-S)

change in insulin secretion in the mixed-meal tolerance test (MMTT) - combined parameter

Time Frame: 3 weeks, 1 year

change in insulin secretion in the mixed-meal tolerance test (MMTT) - combined parameter

change in insulin sensitivity in the mixed-meal tolerance test (MMTT) - combined parameter

Time Frame: 3 weeks, 1 year

change in insulin sensitivity in the mixed-meal tolerance test (MMTT) - combined parameter

Secondary Outcomes

  • change in parameters of autonomic neuropathy - measures of cardio-autonomic neuropathy (SANN, MSDD)(3 weeks, 1 year)
  • inflammatory reaction in subcutaneous adipose tissue (SCAT analysis on protein and RNA level - IL-1; IL1beta, IL-6)(3 weeks, 1 year)
  • change in parameters of peripheral - vibration threshold, thermal sensitivity and pain thresholds(3 weeks, 1 year)

Study Sites (2)

Loading locations...

Similar Trials